NASDAQ:RKDAArcadia Biosciences Stock Price, Forecast & News

Arcadia Biosciences' stock was trading at $3.17 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RKDA shares have increased by 21.5% and is now trading at $3.85. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcadia Biosciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Arcadia Biosciences.

Arcadia Biosciences is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Arcadia Biosciences.

Arcadia Biosciences Inc (NASDAQ:RKDA) posted its quarterly earnings data on Wednesday, May, 13th. The basic materials company reported $0.29 EPS for the quarter, beating the Zacks' consensus estimate of ($0.55) by $0.84. The basic materials company earned $0.31 million during the quarter, compared to analyst estimates of $0.60 million. Arcadia Biosciences had a negative return on equity of 180.70% and a negative net margin of 1,035.38%. View Arcadia Biosciences' earnings history.

Shares of Arcadia Biosciences reverse split before market open on Wednesday, January 24th 2018. The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 23rd 2018. An investor that had 100 shares of Arcadia Biosciences stock prior to the reverse split would have 5 shares after the split.

2 brokerages have issued 12-month price objectives for Arcadia Biosciences' shares. Their forecasts range from $14.00 to $16.00. On average, they anticipate Arcadia Biosciences' stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 289.6% from the stock's current price. View analysts' price targets for Arcadia Biosciences.

Media coverage about RKDA stock has been trending negative recently, InfoTrie Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Arcadia Biosciences earned a coverage optimism score of -2.1 on InfoTrie's scale. They also assigned media coverage about the basic materials company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news about Arcadia Biosciences.

Some companies that are related to Arcadia Biosciences include CVR Partners (UAN), Wynnstay Group (WYN), Eden Research (EDEN), Evogene (EVGN), Bion Environmental Technologies (BNET), China Green Agriculture (CGA), SenesTech (SNES), Kiwa Bio-Tech Products Group (KWBT), Cavitation Technologies (CVAT) and ICL Group (ICL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcadia Biosciences investors own include Micron Technology (MU), Corbus Pharmaceuticals (CRBP), NVIDIA (NVDA), Opko Health (OPK), Inovio Pharmaceuticals (INO), Netflix (NFLX), Sorrento Therapeutics (SRNE), Verastem (VSTM), Yield10 Bioscience (YTEN) and Advanced Micro Devices (AMD).

(RKDA) raised $66 million in an initial public offering on Friday, May 15th 2015. The company issued 8,200,000 shares at $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray served as the underwriters for the IPO.

Arcadia Biosciences trades on the NASDAQ under the ticker symbol "RKDA."

Shares of RKDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of RKDA stock can currently be purchased for approximately $3.85.

Arcadia Biosciences has a market capitalization of $33.30 million and generates $1.17 million in revenue each year. The basic materials company earns $-28,810,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis. Arcadia Biosciences employs 44 workers across the globe.

The official website for Arcadia Biosciences is www.arcadiabio.com.

Arcadia Biosciences' mailing address is 202 COUSTEAU PLACE SUITE 105, DAVIS CA, 85018. The basic materials company can be reached via phone at 530-756-7077 or via email at [email protected]